Product Description
ASP0892 is a new DNA vaccine program based on the investigational LAMP-Vax platform.
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Peanut Hypersensitivity|Environmental Hypersensitivity
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03755713 |
0892-CL-1002 | P1 |
Completed |
Environmental Hypersensitivity|Peanut Hypersensitivity |
2021-10-11 |
12% |
2022-08-20 |
|
NCT02851277 |
0892-CL-1001 | P1 |
Completed |
Peanut Hypersensitivity|Environmental Hypersensitivity |
2018-12-06 |
16% |
2019-12-08 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/01/2023 |
News Article |
Peanut Allergy Vaccine Market Research Report 2023 Growth, Recent Trends and Forecast to 2028 by Key Players |